Inversago Pharma to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

MONTREAL, Quebec--(BUSINESS WIRE)--Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that François Ravenelle, Ph.D., Chief Executive Officer, will present at the upcoming 2023 Bloom Burton & Co. Healthcare Investor Conference on Wednesday, April 26, 2023 at 11:00 a.m. ET.

For additional information or to request a meeting with management, please contact conference representatives.

About Inversago Pharma

Inversago Pharma is a privately owned, clinical stage, Canadian biotech company, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting CB1 inverse agonists. Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as diabetic kidney disease (DKD), including diabetic nephropathy (DN), type 1 and type 2 diabetes (T1D / T2D), non-alcoholic steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications like progressive fibrosis-interstitial lung disease (PF-ILD), including idiopathic pulmonary fibrosis (IPF) and other conditions.